Details for Patent: 8,109,918

Which drugs does patent 8,109,918 protect, and when does it expire?

Patent 8,109,918 protects SINUVA and is included in one NDA.

This patent has six patent family members in five countries.

Summary for Patent: 8,109,918

Title:	Sinus delivery of sustained release therapeutics
Abstract:	The invention provides biodegradable implants for treating sinusitis. The biodegradable implants have a size, shape, density, viscosity, and/or mucoadhesiveness that prevents them from being substantially cleared by the mucociliary lining of the sinuses during the intended treatment period. The biodegradable implants include a sustained release therapeutic, e.g., an antibiotic, a steroidal anti-inflammatory agent, or both. The biodegradable implants may take various forms, such as rods, pellets, beads, strips, or microparticles, and may be delivered into a sinus in various pharmaceutically acceptable carriers.
Inventor(s):	Eaton; Donald J. (Los Altos, CA), Moran; Mary L. (Woodside, CA), Brenneman; Rodney (San Juan Capistrano, CA)
Assignee:	Intersect ENT, Inc. (Palo Alto, CA)
Application Number:	12/479,794
Patent Claim Types: see list of patent claims	Use; Delivery; Device;

Drugs Protected by US Patent 8,109,918

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Intersect Ent Inc	SINUVA	mometasone furoate	IMPLANT;IMPLANTATION	209310-001	Dec 8, 2017		RX	Yes	No						TREATMENT OF NASAL POLYPS IN PATIENTS >=18 YEARS OF AGE WHO HAVE HAD ETHMOID SINUS SURGERY USING A CORTICOSTEROID-ELUTING (MOMETASONE FUROATE) IMPLANT

International Family Members for US Patent 8,109,918

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2004222340
Canada	2518960
European Patent Office	1605863
European Patent Office	3103422